Edwards Reinforces Transcatheter Mitral Program With CardiAQ Buy
This article was originally published in The Gray Sheet
Executive Summary
Edwards says that CardiaAQ's mitral valve technology is complementary to its early-stage Fortis program, and that the two development programs will be combined.
You may also be interested in...
CardiAQ Uses Early-Feasibility IDE Paradigm To Bring Trans-Mitral Valve Device To U.S. Clinicians
The California startup was able to leverage a new FDA process for early-feasibility device trials to launch a small U.S. study of its transfemoral and transapical transcatheter mitral valve implantation systems.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.